The Europe RNAi therapeutics market is expected to reach US$ 324.33 million in 2027 from US$ 170.42 million in 2019. The market is estimated to grow with a CAGR of 8.4% from 2020-2027.
The growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions in Europe are the key factors driving the growth of RNAi therapeutics. However, high cost of RNAi therapies is the major factor hindering the market growth in Europe.
RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing number of investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the Europe RNAi Therapeutics market during the forecast period.
According to the WHO, more than 15 million people are currently living with at least one chronic disease in UK. This has propelled the growth of healthcare systems. Extensive R&D activities are being conducted by government institutions and academic research centers to discover new drug delivery technologies and deal with the increasing number of patients suffering from infectious diseases (e.g., pneumonia, meningitis, food poisoning, and flu) and chronic conditions (e.g., cancer, diabetes, and cardiovascular conditions).
Carbapenem-resistant Enterobacteriaceae and, in particular, those with carbapenemases, are an emerging infection problem in a major paediatric hospital in the UK. According to British Lung Foundation, in 2012, 345 people for every 100,000 people had pneumonia. Unfortunately, in the period 2001–10, 214 people for every million died from pneumonia in the UK. Most of the people affected by pneumonia are adults. These numbers show that the cases of infectious diseases, especially caused due to bacteria, are increasing day by day. Furthermore, cancer and diabetes are among the leading causes of mortality. According to Cancer Research UK, in between 2015-2017, there are around 367,000 new cancer cases in the UK every year, that's around 1,000 every day. RNAi therapies have significant potential to provide promising treatment for such extensively increasing diseases. Thus, the staggering number of cases necessitates the need for superior treatments, which, in turn, bolsters the growth of the RNAi therapeutics market.
In Europe there is exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. Growing research activities to develop treatment against COVID-19 is likely to favor the growth of the market. In June 2020, the scientists from University of Oxford have been testing existing drugs as therapies for the new infection. Thus, growing focus on development of therapies against corona virus is likely to favor the growth of the market in the Europe.
Rest of Europe RNAi Therapeutics Market, Revenue and Forecast to 2027 (US$ Mn)
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
EUROPE RNAi THERAPEUTICS MARKET SEGMENTATION
By Molecule Type
- Small Interfering RNAs (siRNA)
- MicroRNA (miRNA)
By Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intradermal Injections
- Intraperitoneal Injections
- Others
By Application
- Oncology
- Cardiovascular
- Respiratory Disorders
- Renal Diseases
- Genetic Disorders
- Neurodegenerative Disorders
- Infectious Diseases
- Others
By End User
- Research and Academic Laboratories
- Hospitals
- Diagnostic Laboratories
By Country
- Germany
- UK
- France
- Italy
- Spain
Company Profiles
- Alnylam Pharmaceuticals, Inc
- Sanofi
- GlaxoSmithKline plc
- Silence Therapeutics
- Arrowhead Pharmaceuticals, Inc
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Molecule Type, Application, Route of Administration, and End User Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
UK, Germany, France, Italy, Russia
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe RNAi Therapeutics Market – By Molecule Type
1.3.2 Europe RNAi Therapeutics Market – By Application
1.3.3 Europe RNAi Therapeutics Market – By Route of Administration
1.3.4 Europe RNAi Therapeutics Market– By End User
1.3.5 Europe RNAi Therapeutics Market – By Country
2. Europe RNAi Therapeutics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe RNAi Therapeutics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 RNAi therapeutics Market - Europe PEST Analysis
4.3 Expert Opinion
5. Europe RNAi Therapeutics Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Growing Investments in RNAi Therapies
5.1.2 Rising Prevalence of Chronic Conditions and Infectious Diseases
5.2 Market Restraints
5.2.1 High Cost for RNAi Therapy Development
5.3 Market Opportunities
5.3.1 Significant Number of Pipeline Candidates for Strategic Alliances
5.4 Future Trends
5.4.1 Rising Emphasis on RNA Technologies
5.5 Impact analysis
6. RNAi Therapeutics Market – Europe Analysis
6.1 Europe RNAi Therapeutics Market Revenue Forecasts and Analysis
7. Europe RNAi Therapeutics Market Analysis and Forecasts To 2027 – By Molecule Type
7.1 Overview
7.2 Europe RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)
7.2.1 Europe RNAi therapeutics Market Revenue and Forecasts to 2027, By Molecule Type (US$ Mn)
7.3 Small Interfering RNAs (siRNA)
7.3.1 Overview
7.3.2 Europe Small Interfering RNAs (siRNA) Market Revenue and Forecast to 2027 (US$ Mn)
7.4 MicroRNA (miRNA)
7.4.1 Overview
7.4.2 Europe MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
8. Europe RNAi therapeutics Market Analysis and Forecasts To 2027 – By Application
8.1 Overview
8.2 Europe RNAi therapeutics Market, By Application 2019 & 2027 (%)
8.2.1 Europe RNAi therapeutics Market Revenue and Forecasts to 2027, By Application (US$ Mn)
8.3 Genetic Disorders
8.3.1 Overview
8.3.2 Europe Genetic Disorders Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Oncology
8.4.1 Overview
8.4.2 Europe Oncology Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Neurodegenerative Disorders
8.5.1 Overview
8.5.2 Europe Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Cardiovascular Disorders
8.6.1 Overview
8.6.2 Europe Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Europe Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Infectious Diseases
8.8.1 Overview
8.8.2 Europe Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
8.9 Renal Diseases
8.9.1 Overview
8.9.2 Europe Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
8.10 Other Disorders
8.10.1 Overview
8.10.2 Europe Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
9. Europe RNAi therapeutics Market Analysis and Forecasts To 2027 – By Route of Administration
9.1 Overview
9.2 Europe RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)
9.2.1 Europe RNAi therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
9.3 Intradermal Injections
9.3.1 Overview
9.3.2 Europe Intradermal Injections Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Pulmonary Delivery
9.4.1 Overview
9.4.2 Europe Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Intravenous Injections
9.5.1 Overview
9.5.2 Europe Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Intraperitoneal Injections
9.6.1 Overview
9.6.2 Europe Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Other Route of Administrations
9.7.1 Overview
9.7.2 Europe Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)
10. Europe RNAi Therapeutics Market Analysis – By End-User
10.1 Overview
10.2 Europe RNAi Therapeutics Market, By End-User 2019-2027 (%)
10.2.1 Europe RNAi Therapeutics Market Revenue and Forecasts to 2027, By End-User (US$ Mn)
10.3 Diagnostic Laboratories
10.3.1 Overview
10.3.2 Europe Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
10.4 Research and Academic Laboratories
10.4.1 Overview
10.4.2 Europe Research and Academic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
10.5 Hospitals
10.5.1 Overview
10.5.2 Europe Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
11. RNAi therapeutics Market Revenue and Forecasts To 2027 – Geographical Analysis
11.1 Europe: RNAi Therapeutics Market
11.1.1 Overview
11.1.2 Europe: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.3 Europe RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.4 Europe RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.5 Europe RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.6 Europe RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.1.7 Europe: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
11.1.8 Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 Germany RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.8.3 Germany RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.8.4 Germany RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.8.5 Germany RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.1.9 UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 UK RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.9.3 UK RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.9.4 UK RNAi Therapeutics Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
11.1.9.5 UK: RNAi Therapeutics Market, End User – Revenue and Forecast to 2027 (USD Million)
11.1.10 France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 France RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.10.3 France RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.10.4 France RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.10.5 France RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.1.11 Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.1 Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.2 Spain RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.11.3 Spain RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.11.4 Spain RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.11.5 Spain RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.1.12 Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.12.1 Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.12.2 Italy RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.12.3 Italy RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.12.4 Italy RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.12.5 Italy RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
12. Impact of COVID-19 Pandemic on Europe RNAi therapeutics Market
12.1 Europe: Impact Assessment of COVID-19 Pandemic
13. Company Profiles
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Alnylam Pharmaceuticals, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Arrowhead Pharmaceuticals, Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe RNAi therapeutics Market Revenue and Forecasts To 2027, By Molecule Type (US$ Mn)
Table 2. Europe RNAi therapeutics Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 3. Europe RNAi therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
Table 4. Europe RNAi Therapeutics Market Revenue and Forecasts To 2027, By End-User (US$ Mn)
Table 5. Europe RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 6. Europe RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 7. Europe RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 8. Europe RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 9. Germany RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 10. Germany RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 11. Germany RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 12. Germany RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 13. United Kingdom RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 14. United Kingdom RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 15. UK: RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million).
Table 16. UK: RNAi Therapeutics Market, End User – Revenue and Forecast to 2027 (USD Million)
Table 17. France RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 18. France RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 19. France RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 20. France RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 21. Spain RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 22. Spain RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 23. Spain RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 24. Spain RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 25. Italy RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 26. Italy RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 27. Italy RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 28. Italy RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 29. Glossary of Terms, RNAi Therapeutics Market
LIST OF FIGURES
Figure 1. RNAi Therapeutics Market Segmentation
Figure 2. Europe RNAi Therapeutics Market Overview
Figure 3. Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market
Figure 4. UK is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Europe RNAi Therapeutics Market - Leading Country Markets (US$ Mn)
Figure 6. RNAi Therapeutics Market - Europe PEST Analysis
Figure 7. RNAi Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Europe RNAi Therapeutics Market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. Europe RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)
Figure 10. Europe Small Interfering RNAs (siRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. Europe MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Europe RNAi therapeutics Market, By Application 2019 & 2027 (%)
Figure 13. Europe Genetic Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Europe Oncology Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Europe Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Europe Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Europe Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Europe Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Europe Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Europe Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Europe RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)
Figure 22. Europe Intradermal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Europe Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Europe Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Europe Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Europe Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. Europe RNAi Therapeutics Market, by End-User 2019 & 2027 (%)
Figure 28. Europe Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. Europe Research and Academic Laboratories Mark et Revenue and Forecasts to 2027 (US$ Mn)
Figure 30. Europe Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 31. Europe: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 32. Europe RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 33. Europe: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 34. Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 35. UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 36. France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 37. Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 38. Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 39. Impact of COVID-19 Pandemic in Europe Country Markets
- Sanofi
- GlaxoSmithKline plc
- Silence Therapeutics
- Alnylam Pharmaceuticals, Inc
- Arrowhead Pharmaceuticals, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Europe RNAi Therapeutics Market
Oct 2020
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Oct 2020
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2020
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Oct 2020
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Oct 2020
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Oct 2020
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Oct 2020
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)
Oct 2020